UroGen Pharma (URGN) Gross Profit Growth (5y) (2023 - 2026)

UroGen Pharma (URGN) Gross Profit Growth (5y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 UroGen Pharma 2.05 Bn 1.91 Bn 46.82 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 48.03%
Dec 31, 2025 36.41%
Sep 30, 2025 50.34%
Jun 30, 2025 129.58%
Jun 30, 2024 305.02%
Sep 30, 2023 91.78%
Jun 30, 2023 232.50%
Mar 31, 2023 211.37%